Last reviewed · How we verify

paracetamol /droperidol

University Hospital, Limoges · Phase 3 active Small molecule

Paracetamol reduces pain and fever through inhibition of prostaglandin synthesis, while droperidol is an antipsychotic and antiemetic that blocks dopamine receptors.

Paracetamol reduces pain and fever through inhibition of prostaglandin synthesis, while droperidol is an antipsychotic and antiemetic that blocks dopamine receptors. Used for Acute pain management with nausea/vomiting prevention.

At a glance

Generic nameparacetamol /droperidol
SponsorUniversity Hospital, Limoges
Drug classAnalgesic/Antipyretic combined with Antipsychotic/Antiemetic
TargetCyclooxygenase (COX) enzymes; Dopamine D2 receptor
ModalitySmall molecule
Therapeutic areaPain Management, Acute Care
PhasePhase 3

Mechanism of action

This is a combination drug pairing paracetamol (acetaminophen), which works centrally to inhibit cyclooxygenase enzymes and reduce prostaglandin production, with droperidol, a butyrophenone antipsychotic that antagonizes dopamine D2 receptors to provide antiemetic and sedative effects. The combination is designed to provide analgesia with antiemetic and anxiolytic benefits, particularly useful in acute pain management settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: